AKT1 and acute myeloid leukemia: Interestingly, these cells were more sensitive to treatment with the Akt inhibitor, but less responsive to the PP2A activator FTY720, supporting the role of PP2A-B55α holoenzyme in the regulation of Akt phosphorylation in AML.